Roche Diagnostics sales beat market average:
This article was originally published in Clinica
Roche Diagnostics saw its sales rise 14% to SwF5.3 billion ($3.5 billion) in 1999, substantially faster than the global average, the Swiss company says. All four business units contributed to the strong sales. Operating profit rose 29% to SwF771 million. The company is bringing together some diagnostic and therapeutic products to provide integrated healthcare solutions, with packages available for conditions such as HIV, breast cancer and influenza.
You may also be interested in...
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.